JP2017518319A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518319A5
JP2017518319A5 JP2016571301A JP2016571301A JP2017518319A5 JP 2017518319 A5 JP2017518319 A5 JP 2017518319A5 JP 2016571301 A JP2016571301 A JP 2016571301A JP 2016571301 A JP2016571301 A JP 2016571301A JP 2017518319 A5 JP2017518319 A5 JP 2017518319A5
Authority
JP
Japan
Prior art keywords
compound
crystalline form
pxrd pattern
solution
dissolving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016571301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/034371 external-priority patent/WO2015188045A1/en
Publication of JP2017518319A publication Critical patent/JP2017518319A/ja
Publication of JP2017518319A5 publication Critical patent/JP2017518319A5/ja
Priority to JP2021048244A priority Critical patent/JP2021113192A/ja
Priority to JP2023064709A priority patent/JP2023089125A/ja
Priority to JP2024179614A priority patent/JP2025004239A/ja
Pending legal-status Critical Current

Links

JP2016571301A 2014-06-06 2015-06-05 結晶形 Pending JP2017518319A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021048244A JP2021113192A (ja) 2014-06-06 2021-03-23 結晶形
JP2023064709A JP2023089125A (ja) 2014-06-06 2023-04-12 結晶形
JP2024179614A JP2025004239A (ja) 2014-06-06 2024-10-15 結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008786P 2014-06-06 2014-06-06
US62/008,786 2014-06-06
PCT/US2015/034371 WO2015188045A1 (en) 2014-06-06 2015-06-05 Crystal forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021048244A Division JP2021113192A (ja) 2014-06-06 2021-03-23 結晶形

Publications (2)

Publication Number Publication Date
JP2017518319A JP2017518319A (ja) 2017-07-06
JP2017518319A5 true JP2017518319A5 (enExample) 2018-06-28

Family

ID=54767417

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016571301A Pending JP2017518319A (ja) 2014-06-06 2015-06-05 結晶形
JP2021048244A Pending JP2021113192A (ja) 2014-06-06 2021-03-23 結晶形
JP2023064709A Pending JP2023089125A (ja) 2014-06-06 2023-04-12 結晶形
JP2024179614A Pending JP2025004239A (ja) 2014-06-06 2024-10-15 結晶形

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021048244A Pending JP2021113192A (ja) 2014-06-06 2021-03-23 結晶形
JP2023064709A Pending JP2023089125A (ja) 2014-06-06 2023-04-12 結晶形
JP2024179614A Pending JP2025004239A (ja) 2014-06-06 2024-10-15 結晶形

Country Status (8)

Country Link
US (2) US9321807B2 (enExample)
EP (2) EP4403223B1 (enExample)
JP (4) JP2017518319A (enExample)
CN (1) CN106413736A (enExample)
AU (2) AU2015269306B2 (enExample)
CA (1) CA2948902C (enExample)
MX (1) MX373056B (enExample)
WO (1) WO2015188045A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188045A1 (en) * 2014-06-06 2015-12-10 Abbvie Inc. Crystal forms
WO2021137256A1 (en) 2020-01-03 2021-07-08 Mylan Laboratories Limited Polymorphic forms of glecaprevir
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604234A (en) * 1991-09-05 1997-02-18 Abbott Laboratories Substituted thiol macrolactam immunomodulators
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
ME02024B (me) * 2008-07-22 2015-05-20 Merck Sharp & Dohme Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
CA2770338A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
HUE028384T2 (en) 2010-09-21 2016-12-28 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
BR112014003798A2 (pt) 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
US9469673B2 (en) * 2012-07-12 2016-10-18 Abbvie Inc. Crystaline forms of HCV inhibitor
MX2016005393A (es) * 2013-10-25 2016-08-11 Abbvie Inc Metodos para tratar vhc.
WO2015188045A1 (en) * 2014-06-06 2015-12-10 Abbvie Inc. Crystal forms

Similar Documents

Publication Publication Date Title
JP2019526717A5 (enExample)
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
HRP20241239T1 (hr) Novi heterociklički derivati korisni kao shp2 inhibitori
JP2013032389A5 (enExample)
JP2009523771A5 (enExample)
WO2016020320A8 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
EP3283470A4 (en) Processes for producing 2,5-furandicarboxylic acid and derivatives thereof and polymers made therefrom
JP2012092123A5 (enExample)
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
BR112015023218A2 (pt) formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas
EP4327880A3 (en) Solid state form of ribociclib succinate
HK1256614A1 (zh) 经取代的1,2-二氢-3h-吡咯并[1,2-c]咪唑-3-酮抗菌化合物
WO2014145686A3 (en) Novel cyclosporin derivatives and uses thereof
WO2016135747A3 (en) Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
WO2017220042A3 (zh) 氨力农的药物组合物及其在高血压治疗中的应用
WO2015002755A3 (en) Compounds for the treatment of malaria
JP2019520713A5 (enExample)
JP2017014205A5 (enExample)
WO2015128882A3 (en) Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
HK1206747A1 (en) Crystalline forms of an hcv inhibitor
WO2017094031A3 (en) Novel process for preparation of apremilast
JP2016539066A5 (enExample)